Exhibit 16.1

June 28, 2002

Office of the Chief Accountant
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Dear Sir or Madam:

The representations made in this letter are based solely on discussions with and
representations from the engagement partner and manager on the audits of the
financial statements of this registrant. Those individuals are no longer with
Arthur Andersen LLP. We have read the first four paragraphs of Item 4 included
in the Form 8-K dated June 28, 2002 of Interleukin Genetics, Inc. to be filed
with the Securities and Exchange Commission and are in agreement with the
statements therein.

Very truly yours,


/s/ Arthur Andersen LLP

Arthur Andersen LLP

cc:  Mr. Fenel Eloi, Chief Financial Officer and Chief Operating Officer,
     Interleukin Genetics, Inc.